Bolt Biotherapeutics, Inc. Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, Less than 12 Months
Bolt Biotherapeutics, Inc. (BOLT) had Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, Less than 12 Months of $0 as of 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Notes › Debt and Equity Securities › Debt Securities, Available-for-Sale, Unrealized Loss Position
us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months · last filed 2026-08-11
- 2026-06-30: Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, Less than 12 Months $0.00.
- 2026-03-31: Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, Less than 12 Months $4.00K.
- 2025-12-31: Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, Less than 12 Months $0.00.
- 2025-09-30: Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, Less than 12 Months $0.00.
| Period end | Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, Less than 12 Months |
|---|---|
| 2026-06-30 | $0.00 10-Q · filed 2026-08-11 |
| 2026-03-31 | $4.00K 10-Q · filed 2026-05-12 |
| 2025-12-31 | $0.00 10-Q · filed 2026-08-11 |
| 2025-09-30 | $0.00 10-Q · filed 2025-11-12 |
| 2025-06-30 | $6.00K 10-Q · filed 2025-08-14 |
| 2025-03-31 | $5.00K 10-Q · filed 2025-05-12 |
| 2024-12-31 | $0.00 10-K · filed 2026-03-12 |
| 2024-06-30 | $21.00K 10-Q · filed 2024-08-13 |
| 2024-03-31 | $18.00K 10-Q · filed 2024-05-14 |
| 2023-12-31 | $12.00K 10-K · filed 2025-03-24 |
| 2023-09-30 | $16.00K 10-Q · filed 2023-11-09 |
| 2023-06-30 | $24.00K 10-Q · filed 2023-08-07 |
| 2023-03-31 | $21.00K 10-Q · filed 2023-05-11 |
| 2022-12-31 | $65.00K 10-K · filed 2024-03-21 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Enveric Biosciences, Inc. (ENVB) | United States | $0.007B | -0.63 |
| SYNLOGIC, INC. (SYBX) | United States | $0.007B | |
| Acurx Pharmaceuticals, Inc. (ACXP) | United States | $0.007B | -0.97 |
| CNS Pharmaceuticals, Inc. (CNSP) | United States | $0.007B | |
| Apimeds Pharmaceuticals US, Inc. (APUS) | United States | $0.008B | |
| Ernexa Therapeutics Inc. (ERNA) | United States | $0.006B | |
| InMed Pharmaceuticals Inc. (INM) | $0.008B | -0.65 | |
| Pulmatrix, Inc. (PULM) | United States | $0.006B | |
| Ensysce Biosciences, Inc. (ENSC) | United States | $0.008B | -0.37 |
| EXICURE, INC. (XCUR) | United States | $0.008B | -1.54 |